Index

3Ds, 23
Abbreviated Mental Test Score, 11
abstract ability assessment, 16
acute anxiety reactions, 107
advocacy for the elderly, 125–126
age-associated memory impairment (AAMI), 36
age of onset of illness, 8
agoraphobia, 103
AIDS, 3
AIDS dementia, 36
dementias associated with, 36
prevalence in the elderly, 113
alcohol use disorders, 113–117
alcohol consumption and dementia, 115
and suicide risk, 115
effects of excessive consumption in the elderly, 114–115
late onset alcoholism, 115
management of alcohol problems in the elderly, 115–117
metabolism of alcohol in later life, 114
outcome, 117
prevalence, 113–114
Alzheimer's Association (USA), 2
Alzheimer's disease (AD), 130
amyloid hypothesis, 32–33
apolipoprotein E status, 19
disease process, 32–33
genetic factors, 33
mixed vascular and Alzheimer dementia, 35
neurofibrillary tangles, 32–33
potential developments in treatment, 45
prevalence of depression, 72
risk factors, 33
search for a vaccine, 3,
See also dementia
Alzheimer's Disease Assessment Scale Cognitive subscale (ADAS-Cog), 16
Alzheimer's Disease International (ADI), 2
Alzheimer's Society (UK), 2
American Association of Geriatric Psychiatry (AAGP), 130
American Psychiatric Association, 130
amyloid hypothesis of AD, 32–33
anaemias, 18
angiotensin converting enzyme (ACE) inhibitors, 83
anticholinergic antidepressants, 28
anticholinergic drugs, 25
delirium caused by, 60
anticonvulsants use in BPBSD, 55
antidepressants, 28
use in BPBSD, 54
antipsychotic drugs use in BPBSD, 53–54
anxiety, See neurotic disorders
apolipoprotein E, 33
apolipoprotein E status and AD risk, 19
Appleby, Louis, 133
Arie, Tom, 1, 121, 130
aripiprazole, 53
arteriosclerotic heart disease, 81
arthritis, 3
assessing the elderly psychiatric patient, 5–20
abstract ability, 16
access to diagnostic resources, 5–6
age of onset of illness, 8
capacity assessments, 16–18
cognitive assessment, 10–16
cognitive assessment instruments, 11–16
community based assessment, 125
executive impairment, 14–16
frontal lobe impairment, 14–16
generic testing, 19
GP assessment and referral, 6
history taking, 8
laboratory services, 5–6
medical co-morbidity, 5–6
mental status examination, 8–10
monitoring change over time, 11, 14
multidisciplinary team approach, 5
neuroimaging, 6
perseveration, 15–16
physical examination, 18
potential benefits of early detection, 11
primary care assessment and referral, 6
referral to other specialists for assessment, 19–20
role of the carer/informant, 6–7
role of the family, 6–7
setting for the assessment, 5
Index

special features with elderly patients, 5
special investigations, 18–19
structural brain imaging, 19
Verbal Fluency tests, 14–15
where to conduct the assessment, 5
Automatic Thought Questionnaire, 105

barbiturate dependence problem, 117
Beck Depression Inventory, 105
behavioural and psychological symptoms of dementia (BPSD), 49–55
antipsychotic drugs, 53–54
assessment of the patient, 51
in Alzheimer's original patient, 49
management principles, 51–52
natural history, 50–51
non-pharmacological management, 53
origin of the term, 49
pharmacological management, 53–55
specific symptoms, 49–50
symptoms at different stages, 50–51
use of anticonvulsants, 55
use of antidepressants, 54
use of cholinesterase inhibitors, 54–55
benign senescent forgetfulness, 28
benzodiazepines, 107, 116
adverse effects in the elderly, 117–118
over-use and dependency in the elderly, 117–118
bipolar disorders and mania, 77–84
age of onset, 79–80
classification, 78–79
clinical course, 82
definition, 77
delirium, 60
determinants for later life onset, 82–83
epidemiology, 79
involvement of carers and family, 84
late onset, 78–80
lithium carbonate use in old age, 83–84
mood stabilisers, 83–84
neuromaging, 81
neurological comorbidity, 80–81
outcome, 82
pathological laughing and crying, 80
patophysiology, 80–81
risk factors for later life onset, 82–83
special considerations, 78
treatment, 83–84
vascular mania hypothesis, 81
bone diseases, 19
BPSD, see behavioural and psychological symptoms of dementia
brain haemorrhage, 19
brain tumour, 19
bupropriol, 61, 76
Cambridge Cognitive Examination (CAMCOG), 16
Canadian Association of Geriatric Psychiatry, 130
capacity assessments, 16–18
carbamazepine, 84
carers
biopolar disorder patients, 84
respite care, 125
role in assessment of the patient, 6–7
role in the therapeutic alliance, 6–7
support and respite for, 52
support through education, 53
CARITAS principles, 122–123
cataracts, 18
cerebral reserve theory of dementia, 3–4
cerebrovascular adverse events (CVAEs)
risk with antipsychotic drugs, 54
cerebrovascular disease, 81
cholinesterase inhibitors, 43–44, 54–55
chronic fatigue, 108
chronic lymphatic leukaemia, 18
chronic pain, 108
climidine, 63
citalopram, 54–55
climate change, 3
clinical implications
links between depression and dementia, 29–30
clinical neuroscience, 130–132
future training in, 132–133
clinical psychologist
referral to, 19–20
Clock Drawing Test (CDT), 11–14
clozapine, 108
CLOX test, 16
cognitive assessment instruments, 11–16
cognitive behaviour therapy (CBT), 76, 104–105, 116
cognitive disorders
neuromaging, 6
cognitive impairment
and depression, 72–73
cognitive impairment not dementia (CIND), 36
Cohen Mansfield Agitation Inventory (CMAI), 51
community based assessment, 125
community-based care and support, 2
computerised tomography (CT), 19
Confusion Assessment Method (CAM), 59
Consorotium to Establish a Registry for Alzheimer's Disease (CERAD), 14
coronary artery disease, 6
Creuzfeldt–Jakob disease, 19
Cummins, Jeffrey, 133
cytokines
role in delirium, 61
Delayed Recall screening instrument, 11
delirium, 57–67
eaetiology, 60–61
and bipolar disorder, 60
Index

139

and dementia, 59
and depression, 59–60
and mania, 60
and neurotic disorders, 101
and quality of hospital care, 57, 67
caused by anticholinergic drugs, 60
clinical features, 57–59
course and prognosis, 63–64
diagnosis, 57–59
deral diagnosis, 59–60
epidemiology, 61–62
hospital-acquired delirium, 57
hospital incidence rates, 61–62
hyperactive form, 58
hypoaactive form, 58
neuropsychophysics, 60–61
outcome, 63–64
prevalence and incidence rates in the elderly, 61–62
prevention, 66–67
relationship with depression and dementia, 27
risk factors, 62–63
role of cytokines, 61
delirium differential diagnosis, 23–30
family history, 25–27
history of the onset, 23–25
medical history, 25
delirium management, 64–66
address the underlying causes, 64–65
maintain behaviour control, 65
prevent common complications, 65–66
rehabilitation, 66
Delirium Rating Scale (DRS), 59
delirium tremens, 58
dementia
AIDS dementia, 36
and alcohol consumption, 115
and delirium, 59
and neurotic disorders, 101
associated with syphilis, 36
cerebral reserve theory, 3–4
definitions, 31
dementia with Lewy bodies (DLB), 35
dementias associated with alcohol abuse, 36
depression as risk factor, 69–72
diagnostic criteria, 31
ever-onset dementia, 19, 37–38
epidemiology, 37–38
false theories about, 27–28
f elic factors, 33, 37–38
implications of demographic ageing, 2–3
mild cognitive impairment (MCI), 36–37
mixed vascular and Alzheimer dementia, 35
natural history, 38–39
prevalence, 2–3, 37
relationship with depression, 28–30
relationship with depression and delirium, 27
reversible dementia, 24–25
risk factors, 37–38
symptoms of mild dementia, 38
symptoms of moderate dementia, 38–39
symptoms of severe dementia, 39
types and causes, 31–37
uncommon dementias, 36,
See also Alzheimer's disease (AD);
behavioural and psychological symptoms of
dementia (BPSD);
frontotemporal dementias (FTD);
vascular dementia (VaD)
dementia assessment and diagnosis, 39–41
informant history, 39–40
medical assessment, 40–41
neuroimaging, 6
neuropsychological tests, 41
special investigations, 41
dementia differential diagnosis, 23–30
family history, 25–27
history of the onset, 23–25
medical history, 25
dementia management
carer support, 45
cholinesterase inhibitors, 43–44
comorbid medical conditions, 42–43
drug treatment of VaD, 44
drug treatments, 43–45
end of life care, 46
future developments, 46
impacting the diagnosis, 42
implications of the diagnosis, 42
memantine, 44
outcome, 46
social management and support, 45
dementia praecox, 87
dementia with Lewy bodies (DLB), 35,
See also dementia
demographic ageing
implications for health care, 2–4
increase in dementia prevalence, 2–3
social and economic implications, 3
depression
and cognitive impairment, 72–73
and delirium, 59–60
and loss in old age, 69
and losses associated with old age, 27
and neurotic disorders, 100–101
and personal care, 10
classification, 69
comorbidities, 69–73
due to a medical condition, 72
efficacy-effectiveness gap in treating older people, 76–77
electroconvulsive therapy (ECT), 77
epidemiology, 75
false theories about, 27–28
in Alzheimer's disease, 72
nosology, 69
Index

outcome, 77
pathophysiology, 74
psychotherapeutic treatments, 76
relationship with delirium and dementia, 27
relationship with dementia, 28–30
risk factor for dementia, 69–72
risk factors, 69–72
suicide risk, 73–74
treatment, 75–77
vascular depression hypothesis, 73
depression differential diagnosis, 23–30
family history, 25–27
history of the illness, 23–25
medical history, 25
Detre, Thomas, 132
developing world
prevalence of dementia, 2–3
diabetes, 3, 18–19, 81
differential diagnosis, 23–30
delirium, 59–60
false theories of depression and dementia, 27–28
family history, 25–27
history, 23–25
linkage between depression and dementia, 28–30
medical history, 25
neurotic disorders, 100–102
onset of illness, 23–25
progression of the illness, 23–25
relationship between the ‘3Ds’, 27
digoxin, 63
disinhibition syndrome, 80
diuretics, 19, 83
donepezil, 43
dopamine agonist drugs, 61
drug interactions, 25
drug toxicity, 25
Dysfunctional Attitude Scale, 105
dysthymia, 69
early-onset dementia, 19, 37–38
electrocardiogram, 19
electroconvulsive therapy (ECT), 77
electroencephalography, 19
electrolyte imbalances, 6
epilepsy, 19
executive impairment assessment, 14–16
extra-pyramidal side effects
antispsychotic drugs, 54
eyesight impairment, 18
family
role in the assessment of the patient, 6–7
role in the therapeutic alliance, 6–7
family history, 25–27
family involvement
bipolar disorder patients, 84
fatigue syndromes, 104
fibromyalgia, 104, 108
focal atrophy, 19
focal signs, 81
Folstein, see Mini-mental State Examination (MMSE)
frontal assessment battery (FAB), 16
frontal lobe impairment assessment, 14–16
frontotemporal dementias (FTD), 19, 36, See also dementia
future of psychiatry of old age, 129–135
age-based vs. needs-based services, 133–135
developments in clinical neuroscience, 130–132
developments in geriatric medicine, 129
developments in geriatric services, 133–135
effects of developments in psychiatry, 129
future training in clinical neuroscience, 132–133
historical influences, 129–130
galantamine, 43
generalised anxiety disorder (GAD), 102, 107
genetic factors in dementia, 33, 36–38
genetic testing, 19
geriatric medicine, 129–130
emergence of, 1–2
gerontology
emergence of, 1–2
glucocorticoid cascade hypothesis, 29
government health policy
service provision for elderly people, 2
GPCOG screening instrument, 11
haloperidol, 53, 65
head injury, 81
hearing impairment, 18
heart failure, 6
hepatic dysfunction, 6
hippocampal volume
and AD, 19
and depression, 74
reduction in depression and dementia, 28–29
history of mental illness care, 1–2
HIV tests, 19
hydrocephalus, 19
hyperactive delirium, 58
hypertension, 3, 81
hypoaactive delirium, 58
hypokalaemia, 19
hypoponataemia, 19
hypothalamic pituitary adrenal (HPA) axis, 133
hypothyroidism, 6
iatrogenesis
prescribed medicines in the elderly, 117–118
iatrogenic substance-induced psychotic symptoms, 93
illicit substances abuse in the elderly, 117
infection
blood tests, 18
insomnia, 102
International Psychogeriatric Association (IPA), 11, 49, 130
interpersonal psychotherapy, 76, 116
Jorm, Tony, 29
Kandel, Eric, 131
lamotrigine, 84
late-onset schizophrenia (LOS), 87, See also schizophrenia (late-onset), 87
late paraphrenia, 87
leisure needs of elderly people, 126
levodopa, 61
Lewy, Friedrich, 35
lithium carbonate
use in old age, 83–84
liver function tests, 19
lorazepam, 65, 107
losses associated with old age and depression, 27
lumbar puncture, 19
macrocytosis, 18
magnetic resonance imaging (MRI), 6, 19
major depression, 69
malaria, 3
mania, See bipolar disorders and mania
marital/family therapy, 116
medical care for the elderly, 124–125
medical comorbidities, 5–6, 25
memantine, 44
mental illness
history of care and interventions, 1–2
mild cognitive impairment (MCI), 28, 36–37
Mini-Cog screening instrument, 11, 14
Mini-mental State Examination (MMSE), 11–12, 59
mirtazapine, 76
monoamine oxidase inhibitors (MAOIs), 77
Montreal Cognitive Assessment (MoCA), 11
mood disorders, See bipolar disorders and mania; depression
mood stabilisers, 83–84
multidisciplinary team, 5, 123
National Health Service (NHS), 130
creation of geriatric medicine, 1–2
neurothenia, 104
neurofibrillary tangles in AD, 32–33
neuroimaging
use in assessment and diagnosis, 6
neuropathophysiology
delirium, 60–61
Neuropsychiatric Inventory (NPI), 51
neuropsychologist
referral to, 19–20
neurotic disorders, 95–108
acute anxiety reactions, 107
aetiology, 97–98
and delirium, 101
and dementia, 101
and depression, 100–101
and physical illness, 102
and schizophrenia, 101
and sleep disorders, 102
behavioural disturbance, 100
characteristics, 95
classification, 95
clinical features, 98–100
cognitive behavioural therapy (CBT), 104–105
destabilisation factors, 97–98
differential diagnosis, 100–102
drug treatments, 106–108
epidemiology, 98
generalised anxiety disorder (GAD), 102, 107
hysterical symptoms, 100
management, 104–108
obsessive-compulsive disorder (OCD), 103, 108
panic disorder, 103, 107–108
phobic disorders, 103, 108
post-traumatic stress disorder (PTSD), 103, 108
psychodynamic therapy, 105–106
psychological interventions, 104–106
psychological symptoms, 99
restitution factors, 98
sleep disturbance, 100
somatic symptoms, 99–100
somatoform disorders, 99–100, 103–104, 108
vulnerability factors, 97
non-steroidal anti-inflammatory drugs (NSAIDs), 83
obesity, 3
O’Brien, John, 133
obsessive-compulsive disorder (OCD), 103, 108
olanzapine, 53–55, 65, 84
oxazepam, 107
oxcarbazepine, 84
pandemic influenza, 3
panic disorder, 103, 107–108
paraphrenia, 87
parathyroid disease, 19
Parkinsonism, 54
Parkinson’s disease, 35
Parkinson’s disease dementia (PDD), 44
paroxetine, 107–108
pathological laughing and crying, 80
periodic leg movements syndrome, 102
perseveration, 15–16
Index

142

personal care
and mood disorders, 10
personality disorders, 108–112
adjustment to ageing, 108–109
and psychiatric disorders, 111
characteristics, 109
classification, 109
management in old age, 112
personality and organic brain disorders, 111
prevalence at different ages, 109–111
phenelzine, 77
Philp, Ian, 133
phobic disorders, 103, 108
physical examination of the elderly patient, 18
physical illness and neurotic disorders, 102
physostigmine, 60
Pitt, Brice, 5–6, 130
positron emission tomography (PET), 19
Post, Felix, 10, 129
post-traumatic stress disorder (PTSD), 103, 108
prednisolone, 63
prescribed medications
dependency in the elderly, 117–118
primary prevention, 3–4
problem-solving therapy, 76
pseudodementia, 24–25
psychiatry of old age
future challenges, 2–4
history of development, 1–2
implications of demographic ageing, 2–4
scope of concerns, 1, See also future of psychiatry of old age
psychodynamic therapy, 105–106
psychometric testing, See cognitive assessment instruments
psychosis (late-onset)
historical notes, 87–88
psychotic symptoms, 92–93
iatrogenic substance-induced, 93
public education
mental illness in old age, 4, 125
quetiapine, 84
renal dysfunction, 6
respite care, 125
respirate care, 125
restless legs syndrome, 102
reversible dementia, 24–25
risperidone, 53–55, 65, 84
rivastigmine, 43–44
Roth, Martin, 1, 129
Rowland Universal Dementia Assessment Scale (RUDAS), 11
Royal College of Psychiatrists, 130
Sapolsky, Robert, 29
schizophrenia
and neurotic disorders, 101
classification, 87–88
schizophrenia (early-onset), 88
pharmacological management, 90–91
physical management, 90
psychosocial management, 91
residential care, 91–92
schizophrenia (late-onset), 87–93
and personality disorders, 111
causes of psychotic symptoms, 92–93
clinical features, 89
cognitive change, 90
epidemiology, 89
historical notes, 87–88
neuroimaging, 89–90
pharmacological management, 90–91
physical management, 90
psychosocial management, 91
residential care, 91–92
secondary mania, 79
secondary prevention, 4
selective serotonin reuptake inhibitors (SSRIs), 75–76, 107–108
Self Test screening instrument, 11
sensory impairments, 3, 10, 18
serotonin and noradrenergic reuptake inhibitors (SNRIs), 75–76
sertraline, 54–55, 108
services for older psychiatric patients, 121–127
advocacy, 125–126
CARITAS principles, 122–123
community-based assessment, 125
historical notes, 121
information and advice, 125
innovation, 127
International Consensus Model on Organizations of Care, 121–123
leisure needs, 126
medical care, 124–125
multidisciplinary team, 123
necessary components of a service, 126–127
public education, 125
residential care, 123–124
respite care, 125
spiritual needs, 126
Similarities screening instrument, 11
single photon emission tomography (SPET), 6, 19
sleep apnoea, 102
sleep disorders and neurotic disorders, 102
smoking, 3
sodium valproate/divalproex, 83
somatoform disorders, 99–100, 103–104, 108
speech pathologist, referral to, 19–20
spiritual needs of elderly people, 126
stigma of mental illness and ageing, 125
stress and hippocampal volume, 29
stroke, 19, 60, 81
structural brain imaging, 19
substance abuse in the elderly, 113–118
benzodiazepines, 117–118
iatrogenesis with prescribed medications, 117–118
illicit substances, 117
prescribed medication dependency, 117–118
suicidal ideation, 74
suicide risk
and alcohol use disorders, 115
depression, 73–74
supportive psychotherapy, 76
Sydenham's chorea, 103
syphilis, 19
dementia associated with, 36
tacrine, 43
therapeutic alliance
role of carers and families, 6–7
Tourette's syndrome, 103, 130–131
Trail Making Test, 11
transient ischaemic attack (TIA), 81
tranylcypromine, 77
tricyclic antidepressants (TCAs), 75–76
vascular cognitive impairment, 28
vascular dementia (VaD), 28, 35
drug treatment, 44
mixed vascular and Alzheimer dementia, 35,
See also dementia
vascular depression hypothesis, 28, 73
vascular disease, 3, 19, 28
vascular mania hypothesis, 81
vasculitis, 18
venlafaxine, 107
Verbal Fluency tests, 11, 14–15
very-late-onset schizophrenia-like psychosis (VLOSP), 88
vitamin deficiencies, 6
warfarin, 44
Wertheimer, Jean, 122
Whitehead, Tony, 1
World Psychiatric Association, 2